

Provider Network News

Sarepta Suspends ELEVIDYS for Non-Ambulatory Clients

Background

ELEVIDYS (delandistrogene moxeparvovec-rokl) is an adeno-associated virus vector-based gene therapy indicated for the treatment of ambulatory and non-ambulatory individuals age 4 or older with Duchenne muscular dystrophy (DMD) and a confirmed mutation in the DMD gene. HHSC has been made aware of a safety update for the drug ELEVIDYS (HCPCS code J1413).

Key Details

Sarepta is suspending shipments of ELEVIDYS for non-ambulatory clients.

Action

PCHP will work with in-network providers to halt the administration of ELEVIDYS for non-ambulatory clients while an enhanced immunosuppressive regimen is evaluated. HHSC will update prior authorization criteria based on guidance from regulatory bodies.

Resources

<https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-provides-safety-update-elevidys-and-initiates-steps>
